Exploratory Clinical Study on Fasting in Psoriasis and Psoriatic Arthritis (RiseFast)
NCT06905028
Summary
The RiseFast pilot study will investigate the clinical, metabolic and immunological effects of fasting and plant-based diet (PBD) on patients with psoriasis (PsO) and psoriatic arthritis (PsA) on their gut microbiota. The project will combine clinical assessments, cytometric profiling, and gut microbiota analysis to explore the relationship between fasting, a plant-based diet, and psoriatic disease. The study includes a 7-day fasting period followed by 11 weeks of PBD, with the goal of improving disease activity, quality of life, and understanding the role of gut microbiota in these conditions. This approach could lead to low-cost, accessible therapeutic options with minimal side effects.
Eligibility
Inclusion Criteria: * Active plaque psoriasis (PASI ≥3) or Psoriatic Arthritis fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR) and not meeting MDA criteria * on stable baseline psoriatic treatment for 12 weeks before enrollment * ≥ 18 years old Exclusion Criteria: * Pregnancy or breastfeeding * underweight (BMI ≤18,5) * eating disorder in the last 5 years * severe internal diseases (e.g. renal insufficiency with creatinine \> 2mg/dl) * current practice of vegan diet or fasting within the past 6 months * use of antibiotics within the past 3 months
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06905028